Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 4
1987 1
1994 1
1996 2
2001 1
2003 1
2005 3
2006 2
2008 9
2009 4
2010 3
2011 7
2012 3
2013 6
2014 4
2015 6
2016 5
2017 9
2018 12
2019 2
2020 1
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

76 results
Results by year
Filters applied: . Clear all
Page 1
Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis.
Chadi SA, Malcomson L, Ensor J, Riley RD, Vaccaro CA, Rossi GL, Daniels IR, Smart NJ, Osborne ME, Beets GL, Maas M, Bitterman DS, Du K, Gollins S, Sun Myint A, Smith FM, Saunders MP, Scott N, O'Dwyer ST, de Castro Araujo RO, Valadao M, Lopes A, Hsiao CW, Lai CL, Smith RK, Paulson EC, Appelt A, Jakobsen A, Wexner SD, Habr-Gama A, Sao Julião G, Perez R, Renehan AG. Chadi SA, et al. Among authors: gollins s. Lancet Gastroenterol Hepatol. 2018 Dec;3(12):825-836. doi: 10.1016/S2468-1253(18)30301-7. Epub 2018 Oct 12. Lancet Gastroenterol Hepatol. 2018. PMID: 30318451 Free article.
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, Maughan T, McDonald A, Essapen S, Leslie M, Falk S, Wilson C, Gollins S, Begum R, Ledermann J, Kadalayil L, Sebag-Montefiore D. James RD, et al. Among authors: gollins s. Lancet Oncol. 2013 May;14(6):516-24. doi: 10.1016/S1470-2045(13)70086-X. Epub 2013 Apr 9. Lancet Oncol. 2013. PMID: 23578724 Clinical Trial.
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP, Wilson MS, Scott N, O'Dwyer ST. Renehan AG, et al. Among authors: gollins s. Lancet Oncol. 2016 Feb;17(2):174-183. doi: 10.1016/S1470-2045(15)00467-2. Epub 2015 Dec 17. Lancet Oncol. 2016. PMID: 26705854
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J. Iveson T, et al. Among authors: gollins s. Health Technol Assess. 2019 Dec;23(64):1-88. doi: 10.3310/hta23640. Health Technol Assess. 2019. PMID: 31852579 Free PMC article. Clinical Trial.
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J. Iveson TJ, et al. Among authors: gollins s. Lancet Oncol. 2018 Apr;19(4):562-578. doi: 10.1016/S1470-2045(18)30093-7. Lancet Oncol. 2018. PMID: 29611518 Free PMC article. Clinical Trial.
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.
Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J. Valle JW, et al. Among authors: gollins s. Br J Cancer. 2009 Aug 18;101(4):621-7. doi: 10.1038/sj.bjc.6605211. Br J Cancer. 2009. PMID: 19672264 Free PMC article. Clinical Trial.
In Reply to Habr-Gama et al.
Sun Myint A, Smith FM, Gollins S, Rao C, Pritchard DM. Sun Myint A, et al. Among authors: gollins s. Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):743-744. doi: 10.1016/j.ijrobp.2018.03.033. Int J Radiat Oncol Biol Phys. 2018. PMID: 29893284 No abstract available.
Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication.
Boeckemeier L, Kraehenbuehl R, Keszthelyi A, Gasasira MU, Vernon EG, Beardmore R, Vågbø CB, Chaplin D, Gollins S, Krokan HE, Lambert SAE, Paizs B, Hartsuiker E. Boeckemeier L, et al. Among authors: gollins s. Sci Adv. 2020 May 29;6(22):eaaz4126. doi: 10.1126/sciadv.aaz4126. eCollection 2020 May. Sci Adv. 2020. PMID: 32523988 Free PMC article.
Evaluation of pre-analytical factors affecting plasma DNA analysis.
Markus H, Contente-Cuomo T, Farooq M, Liang WS, Borad MJ, Sivakumar S, Gollins S, Tran NL, Dhruv HD, Berens ME, Bryce A, Sekulic A, Ribas A, Trent JM, LoRusso PM, Murtaza M. Markus H, et al. Among authors: gollins s. Sci Rep. 2018 May 9;8(1):7375. doi: 10.1038/s41598-018-25810-0. Sci Rep. 2018. PMID: 29743667 Free PMC article.
76 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page